Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for immune clues in rare salivary gland cancers

NCT ID NCT06047236

Knowledge-focused Sponsor: University of Erlangen-Nürnberg Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for 300 people with salivary gland tumors (both cancerous and non-cancerous) to learn how the immune system reacts to these rare cancers. Researchers will collect tumor tissue and blood samples before and after treatment to find immune markers that might predict how the disease will progress. The goal is to better understand the disease and pave the way for future immunotherapy treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting for treatment at the participating study centers and meeting the inclusion criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Observational group * Initial diagnosis of a primary salivary gland carcinoma in the head and neck region (no squamous cell carcinomas) * Specimen collection from the center of the tumor when the primary tumor is sufficiently large without that the pathological assessment is impaired 2. Control group 1 * Initial diagnosis of a benign salivary gland tumor in the head and neck region * Specimen collection from the center of the tumor when the primary tumor is sufficiently large without that the pathological assessment is impaired 3. Control group 2 * functional diseases of the nose or ear (patients with the indication for functional ear surgery and rhinoplasty) * Specimen collection with sufficiently large resectate during a functional nose surgery for all groups: * Willingness of patients to collect blood, saliva and stool and consent to the preservation of all samples for study purposes. * Age ≥ 18 years * sufficient cognitive ability of the patients to understand the purpose of the study and to understand the purpose of the study and agree to it Exclusion Criteria: * Distant metastasis at the time of diagnosis and simultaneous second cancers, i.e. at study inclusion * Malignancy in the last 5 years regardless of location (except basal cell carcinoma or cis of the uterine cervix) * Carcinomas for which specimen collection is not possible or likely without compromising the compromise the pathological evaluation * Persistent drug or medication abuse * Patients who are unable or unwilling to comply with protocol and to be treated * Patients who are represented by a legal guardian * Patients who are not suitable for participation in the study due to a language barrier

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign salivary gland tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign neoplasm of salivary gland salivary gland cancer salivary gland carcinoma tumor of salivary gland

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Benign salivary gland tumor Salivary gland tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universitätsklinikum Erlangen, HNO

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

  • Universitätsklinikum Erlangen, Strahlenklinik

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.